B
PHGE
vs
S&P 500
S&P 500
Over the past 12 months, PHGE has underperformed S&P 500, delivering a return of -74% compared to the S&P 500's +16% growth.
Stocks Performance
PHGE vs S&P 500
Performance Gap
PHGE vs S&P 500
Performance By Year
PHGE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biomx Inc
Glance View
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
